Newsroom
84 articles
ImportantThe U.S. Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Niemann-Pick disease, type C (NPC). Miplyffa, in combination with the enzyme inhibitor…
ImportantThe European Medicines Agency (EMA) has suggested expanding the use of the Imvanex smallpox and mpox vaccine to adolescents between the ages of 12 and 17. Evaluation of…
ImportantThe U.S. Food and Drug Administration approved Zurnai, the first nalmefene hydrochloride auto-injector for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients…
ImportantEpimax Ointment and Epimax Paraffin-Free Ointment can harm the eyes if used on the face. Do not prescribe these ointments for use on the face. Tell patients to…
ImportantThe TGA has received reports of serious adverse events in infants and children who have been given compounded wind and colic preparations containing Atropa belladonna (belladonna). We are…
ImportantEurneffy (epinephrine) is an alternative to injectable formulations, EMA’s human medicines committee (CHMP) has recommended granting a marketing authorization in the European Union for Eurneffy (epinephrine), the first…
ImportantEMA’s human medicines committee (CHMP) has concluded its review of the medicine Ocaliva (obeticholic acid) and has recommended that the medicine’s marketing authorisation be revoked, because its benefits…
ImportantTopical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use…
ImportantThe Product Information (PI) documents for all selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) have been aligned to reflect the risk of sexual…
ImportantNew boxed warnings are being added to the patient information leaflets (PIL) of montelukast due to neuropsychiatric reactions as a result of MHRA review More prominent warnings are…
ImportantThe Medicines and Healthcare products Regulatory Agency (MHRA) has today (3 May 2024) approved two new formulations of the medicine cabotegravir (Apretude 30 mg film-coated tablets and Apretude…
ImportantETF recommends updating COVID-19 vaccines to target new JN.1 variant Updated vaccines will help maintain protection against disease as virus continues to evolve, MA’s Emergency Task Force (ETF)…
ImportantPRAC committee latest meeting doesn’t support a causal association between the Glucagon-Like Peptide-1 receptor agonists (GLP-1) and suicidal and self-injurious thoughts and actions The PRAC has concluded that…
ImportantTGA Updated warnings of faricimab (Vabysmo) retinal vasculitis risk Faricimab is indicated for: Neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) Faricimab 6 mg/0.05 mL…
ImportantFDA Warns Consumers about Potential for Dangerous Health Effects that can result from Certain Topical Pain Relief Products The U.S. Food and Drug Administration is warning consumers not…
Talk to our experts and get tailored solutions to help you stay compliant and move forward with confidence.
Submit RFI/RFP
Request Consultation
Submit RFI/RFP